Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial - Giugliano, RP; Pedersen, TR; Park, J-G; De, Ferrari GM; Gaciong, ZA; Ceska, R; Toth, K; Gouni-Berthold, I; Lopez-Miranda, J; Schiele, F; Mach, F; Ott, BR; et al. (Lancet, 2017)